NCT03628131

Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors

Safety and Efficacy of Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors

• Status: Unknown
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: Samsung Medical Center · Academic / Other
• Sex: All
• Age: 2 Years – 22 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of combination chemotherapy with Pazopanib in pediatric patients with relapsed/refractory solid tumor

Conditions

• Relapsed Pediatric Solid Tumor
• Refractory Pediatric Solid Tumor

Interventions

Type	Name	Description
DRUG	Pazopanib	Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
DRUG	Ifosfamide	Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
DRUG	Carboplatin	Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib
DRUG	Etoposide	Conventional chemotherapy (Ifosfamide, carboplatin, etoposide) with Pazopanib

Timeline

• Start date: 2018-10-01
• Primary completion: 2023-07-01
• Completion: 2025-07-01
• First posted: 2018-08-14
• Last updated: 2018-09-19

Locations

1 site across 1 country: South Korea